IDH2 and neoplasm: The prevalence of IDH-mutations (IDH-1/IDH-2) is <5% among BTCs, while IDH-mutant tumors typically have lower tumor mutation burden (TMB) and rarely have microsatellite instability or PDL-1 positivity compared to IDH-wild type tumors [71,72,73].